Non-exclusive Drug Discount Agreement for Ticagrelor
Titre original de l'avis
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ticagrelor (ATC-Code nach WHO: B01AC24)
Score d'opportunité
Pourquoi ce score ?
Opportunité
50 / 100
Complexité
20 / 100
Facteurs de risque
No guarantee of minimum quantities; actual demand depends on patient needs and doctor prescriptions.
The buyer may terminate the open-house procedure and existing agreements if exclusive discount agreements are concluded...
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Aperçu
Moderate opportunityFaits clés
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Sep 2026
- Non-exclusive framework agreement for supply of Ticagrelor
- No minimum purchase quantities
Afficher le résumé complet
This is an open-house model for non-exclusive drug discount agreements for the active substance Ticagrelor (ATC B01AC24) with AOK PLUS for Saxony and Thuringia. It is not a traditional procurement; any qualified pharmaceutical company can join at any time until 30 September 2026. No guaranteed volumes or exclusivity are provided. The agreement ends at the latest on 30 September 2026. Submission is electronic via the DTVP portal, and strict confidentiality applies to the procurement documents.
Risques
No guarantee of minimum quantities; actual demand depends on patient needs and doctor prescriptions.
The buyer may terminate the open-house procedure and existing agreements if exclusive discount agreements are concluded...
L'analyse peut être incomplète
Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.
Exigences clés
Technical
- Must be a pharmaceutical company (pharmazeutischer Unternehmer) as per §4(18) AMG
Eligibility
- Must submit declarations on exclusion grounds and Russia sanctions
Administrative
- Must maintain absolute confidentiality of procurement documents
Les exigences peuvent être incomplètes.
Acheteur
Localisation
Erfurt, DEU
Site web
Profil acheteur
Identifiant
DE256878834
Activité
Health
Lots (1)
LOT-0001
Non-exclusive Drug Discount Agreement for Ticagrelor
Enter into a non-exclusive discount agreement for Ticagrelor (ATC B01AC24). No minimum volume, no exclusivity. Open to all qualified pharmaceutical companies. Agreement end date 30 September 2026.
Localisation
Durée
Catégorie
Date limite
Détails des critères
Siehe Kurzbeschreibung
Note sur la valeur
Afficher les données TED originales
Titre original du lot
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ticagrelor (ATC-Code nach WHO: B01AC24)
Description TED originale
Siehe Kurzbeschreibung
Détails de la procédure
- Date de publication
- 05 May 2026
- Langues
- German
Métadonnées de référence
- Base juridique
- 32014L0024
Identifiants de référence
- ID de l'appel d'offres
- 310494-2026
Documents (1)
Appels d'offres similaires
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Score d'opportunité
Pourquoi ce score ?
Opportunité
50 / 100
Complexité
20 / 100
Facteurs de risque
No guarantee of minimum quantities; actual demand depends on patient needs and doctor prescriptions.
The buyer may terminate the open-house procedure and existing agreements if exclusive discount agreements are concluded...
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications